TCTMD
@tctmd.bsky.social
930 followers
110 following
980 posts
Your source for breaking news, topical videos, and slides covering cardiovascular disease and interventions. Register at http://tctmd.com
Posts
Media
Videos
Starter Packs
TCTMD
@tctmd.bsky.social
· 6h
Type 2 MI Diagnoses on the Rise, but Best Course of Action Unknown
Type 2 MI Diagnoses on the Rise, but Best Course of Action Unknown
[email protected]
Wed, 10/08/2025 - 11:00
Caitlin E. Cox
With a mix of causes and comorbidities, type 2 MI patients do better than type 1 early on, then face worse long-term outcomes.
www.tctmd.com
TCTMD
@tctmd.bsky.social
· 8h
Meet the TCT Award Winners
Meet the TCT Award Winners
[email protected]
Wed, 10/08/2025 - 09:19
3 minutes 5 seconds ago
Roxana Mehran gets to know Kenneth Rosenfield and Stephan Windecker, recipients of this year's Master Operator and Career Achievement honors, respectively.
www.tctmd.com
TCTMD
@tctmd.bsky.social
· 1d
Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension
Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension
[email protected]
Tue, 10/07/2025 - 11:54
Todd Neale
In top-line results, the phase III trial demonstrated a “highly clinically meaningful reduction” in 24-hour systolic BP.
www.tctmd.com
TCTMD
@tctmd.bsky.social
· 1d
After Acute HF Admission, Specialist Care Tied to Better Long-term Outcomes
After Acute HF Admission, Specialist Care Tied to Better Long-term Outcomes
[email protected]
Tue, 10/07/2025 - 10:00
Todd Neale
The association was seen across the LVEF range—researchers say all patients should be offered this support.
www.tctmd.com
TCTMD
@tctmd.bsky.social
· 2d
Too Few HF Patients on Guideline-Directed Medical Therapy in VA System
Too Few HF Patients on Guideline-Directed Medical Therapy in VA System
[email protected]
Mon, 10/06/2025 - 15:27
Yael L. Maxwell
Costs aren’t the only barrier to achieving optimal medication adherence, the data indicate.
www.tctmd.com
Reposted by TCTMD
TCTMD
@tctmd.bsky.social
· 5d
Novel Biomarker GDF-15 Helps Risk-Stratify Patients With Suspected ACS
Novel Biomarker GDF-15 Helps Risk-Stratify Patients With Suspected ACS
[email protected]
Fri, 10/03/2025 - 16:10
Todd Neale
As a complement to other biomarkers, the cytokine may aid in the decision to send patients home from the ED or admit them.
www.tctmd.com
Reposted by TCTMD
TCTMD
@tctmd.bsky.social
· 5d
ACC: It’s Time for Clinicians to Address Inflammation in CVD
ACC: It’s Time for Clinicians to Address Inflammation in CVD
[email protected]
Fri, 10/03/2025 - 13:03
Caitlin E. Cox
The new scientific statement, while acknowledging some uncertainties, urges universal screening of hs-CRP.
www.tctmd.com
TCTMD
@tctmd.bsky.social
· 5d
Evolocumab Wins for Primary Prevention in VESALIUS-CV
Evolocumab Wins for Primary Prevention in VESALIUS-CV
[email protected]
Fri, 10/03/2025 - 11:55
L.A. McKeown
The 12,000-patient trial of the PCSK9 inhibitor met its primary endpoints in high-risk individuals with no prior CV events.
www.tctmd.com
TCTMD
@tctmd.bsky.social
· 6d
HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease
HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease
[email protected]
Thu, 10/02/2025 - 16:53
Todd Neale
Patients had less clinical worsening when treated with this “wonder drug,” as one doctor called it, within a year of diagnosis.
www.tctmd.com
TCTMD
@tctmd.bsky.social
· 6d
Risk Factors Present in Nearly All Patients Who Develop CVD
Risk Factors Present in Nearly All Patients Who Develop CVD
[email protected]
Thu, 10/02/2025 - 13:28
Michael O'Riordan
Keeping these factors in check and adhering to the AHA’s Life’s Essential 8, is the best way to prevent CVD, say researchers.
www.tctmd.com
Reposted by TCTMD
TCTMD
@tctmd.bsky.social
· 7d
Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM
Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM
[email protected]
Wed, 10/01/2025 - 14:58
Yael L. Maxwell
The exploratory, post hoc look at the trial shows curves starting to separate by month 1, supporting earlier treatment.
www.tctmd.com
TCTMD
@tctmd.bsky.social
· 7d
Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM
Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM
[email protected]
Wed, 10/01/2025 - 14:58
Yael L. Maxwell
The exploratory, post hoc look at the trial shows curves starting to separate by month 1, supporting earlier treatment.
www.tctmd.com
TCTMD
@tctmd.bsky.social
· 7d
Recognize and Enable Care for Post-MI Psychological Distress: AHA
Recognize and Enable Care for Post-MI Psychological Distress: AHA
[email protected]
Wed, 10/01/2025 - 14:40
L.A. McKeown
It can be a sensitive topic for patients that should be broached gently, without confrontation or judgment, the committee notes.
www.tctmd.com
